CAPLYTA’S Strong Market Adoption Propels Its Rise As A Leading Antipsychotic Therapy | Delveinsight
Intra-Cellular Therapies' CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar de ...
Psychedelic: Exclusive talk with biotech company Enveric Biosciences
In this edition of “Psychedelic”, The Fly conducted an exclusive interview with Joseph Tucker, Chief Executive Officer and Director of Enveric ...
BioSpace4d
AlgoTx Stumbles in Non-Opioid Pain Trial Following Vertex’s Journavx Approval
AlgoTherapeutix blames a “strong placebo effect” for the mid-stage failure for its pain gel ATX01, but the company still ...
The Financial Express3d
Higher tariffs not to blunt India’s competitive edge in US pharma market: Industry
India’s exports of pharmaceuticals to the US were $ 8 billion in 2023-24 while imports stood at just $ 0.4 billion. (Representational Image/Reuters) The threat by US President Donald Trump to ...
BioPharma Dive3d
Recursion CEO launches pre-seed fund in response to NIH cuts
Chris Gibson, Recursion’s head, cited the role small business grants played in helping his company grow its business.